![Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00288-8/MediaObjects/41523_2021_288_Fig1_HTML.png)
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer
![Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies - ScienceDirect Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610822002161-fx1.jpg)
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies - ScienceDirect
![Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy](https://pub.mdpi-res.com/cancers/cancers-14-03848/article_deploy/html/images/cancers-14-03848-g001.png?1660053841)
Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy
![Breast Cancer Basics: Hormonal Therapy (How To Decide If You Should You Take It For 5 Or 10 Years) – IOE Program by Dr. Brian Lawenda Breast Cancer Basics: Hormonal Therapy (How To Decide If You Should You Take It For 5 Or 10 Years) – IOE Program by Dr. Brian Lawenda](https://integrativeoncology-essentials.com/wp-content/uploads/2019/03/Screen-Shot-2019-03-28-at-11.39.28-AM-519x1024.png)
Breast Cancer Basics: Hormonal Therapy (How To Decide If You Should You Take It For 5 Or 10 Years) – IOE Program by Dr. Brian Lawenda
![The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study | npj Breast Cancer The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00366-x/MediaObjects/41523_2021_366_Fig1_HTML.png)
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study | npj Breast Cancer
![The Treatment Plan and Summary provide a brief record of major aspects of breast cancer adjuvant treatment: Fill out & sign online | DocHub The Treatment Plan and Summary provide a brief record of major aspects of breast cancer adjuvant treatment: Fill out & sign online | DocHub](https://www.pdffiller.com/preview/428/167/428167845/large.png)
The Treatment Plan and Summary provide a brief record of major aspects of breast cancer adjuvant treatment: Fill out & sign online | DocHub
![Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy | npj Breast Cancer Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00296-8/MediaObjects/41523_2021_296_Fig1_HTML.png)
Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy | npj Breast Cancer
External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | PLOS ONE
External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | PLOS ONE
![Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1aaed949-5c4f-462b-9551-ec8e88b8e698/tbj.v26.6.cover.jpg?trick=1680548507287)
Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library
![The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment | npj Breast Cancer The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00276-y/MediaObjects/41523_2021_276_Fig1_HTML.png)